Table 2.
Clinicopathologic parameters | Tumor‐free survival | Overall survival | ||||||
---|---|---|---|---|---|---|---|---|
NO. | HR | 95% CI | P | NO. | HR | 95% CI | P | |
Gender | ||||||||
Male | 81 | 0.780 | 0.489–1.244 | 0.297 | 81 | 0.586 | 0.333–1.032 | 0.064 |
Female | 70 | 70 | ||||||
Age (years) | ||||||||
6–20 | 82 | 1.227 | 0.948–1.586 | 0.120 | 82 | 1.239 | 0.911–1.685 | 0.172 |
20–40 | 46 | 46 | ||||||
40–60 | 16 | 16 | ||||||
60–84 | 7 | 7 | ||||||
Location | ||||||||
Femur | 81 | 0.983 | 0.724–1.334 | 0.912 | 81 | 0.859 | 0.585–1.262 | 0.439 |
Tibia | 44 | 44 | ||||||
Elsewhere | 26 | 26 | ||||||
Tumor necrosis rate (%) | ||||||||
≥ 90 | 121 | 0.595 | 0.313–1.133 | 0.114 | 121 | 0.636 | 0.299–1.352 | 0.239 |
≥ 90 | 30 | 30 | ||||||
Cortical destruction | ||||||||
Yes | 127 | 1.215 | 0.622–2.371 | 0.569 | 127 | 1.301 | 0.586–2.887 | 0.518 |
No | 24 | 24 | ||||||
CNOT1 | ||||||||
Negative | 31 | 1.454 | 1.161–1.821 | 0.001a | 31 | 1.676 | 1.277–2.199 | 0.000a |
Low | 46 | 46 | ||||||
Middle | 37 | 37 | ||||||
Strong | 37 | 37 | ||||||
Enneking stage | ||||||||
II | 113 | 2.268 | 1.402–3.668 | 0.001a | 113 | 2.985 | 1.726–5.161 | 0.000a |
III | 38 | 38 |
P < 0.05.